Mary Beth Rios

10.2k citations
129 papers · 7.4k · h-index 53

Impact in

  • Hematology top 0.05%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.05%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 119
    • Chronic Myeloid Leukemia Treatments 108
    • Acute Myeloid Leukemia Research 21
  • Genetics 100
    • Chronic Lymphocytic Leukemia Research 96
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 5
Co-authors
Hagop M. Kantarjian (109 shared papers)Jörge E. Cortes (99 shared papers)Moshe Talpaz (64 shared papers)Susan O’Brien (73 shared papers)Francis J. Giles (51 shared papers)Stefan Faderl (43 shared papers)Guillermo Garcia‐Manero (50 shared papers)Jianqin Shan (29 shared papers)
Journals
Blood (47 papers)Cancer (30 papers)Journal of Clinical Oncology (19 papers)Clinical Cancer Research (2 papers)International Journal of Hematology (2 papers)
Partner nations
United StatesGermanyFrance

In The Last Decade

Mary Beth Rios

128 papers receiving 7.2k citations

Peers

Mary Beth Rios
Comparison fields: 5 of 108
  • Hematology 6.3k
  • Genetics 5.0k
  • Rheumatology 3.5k
  • Public Health, Environmental and Occupational Health 1.2k
  • Pathology and Forensic Medicine 652
Replace Susan O’Brien with:
Susan O’Brien United States
Jianqin Shan United States
Stephen G. O’Brien United Kingdom
Philipp le Coutre Germany
Laurence Legros France
Haifa Kathrin Al‐Ali Germany
Zbigniew Rudzki Australia
Miloslav Beran United States
H. Kantarjian United States
Miloslav Beran United States
Mary Beth Rios relative to Susan O’Brien United States Susan O’Brien's profile →
Citations per field
00.5×1.5×1.8×
Susan O’Brien · 1×
Citations per year

Countries citing papers authored by Mary Beth Rios

Since Specialization
Citations

This map shows the geographic impact of Mary Beth Rios's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Beth Rios with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Beth Rios more than expected).

Fields of papers citing papers by Mary Beth Rios

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Beth Rios. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Beth Rios. The network helps show where Mary Beth Rios may publish in the future.

Co-authors

The 25 scholars most cited alongside Mary Beth Rios, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary Beth Rios Line = papers co-authored together Mary Beth Rios links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
Leukemia ·Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Moshe Talpaz, N. Bekele, Susan O’Brien, Xian Zhou, Rajyalakshmi Luthra, Guillermo Garcia‐Manero, Francis J. Giles, Mary Beth Rios, Srđan Verstovšek, Jörge E. Cortes
2006310
2
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
The Lancet Oncology ·Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jörge E. Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali S. Advani, Susan O’Brien
2012309
3
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
Blood ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Francis J. Giles, Mary Beth Rios, Jianqin Shan, Laurie Letvak, Deborah A. Thomas, Stefan Faderl, Alessandra Ferrajoli, Jörge E. Cortes
2003298
4
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Blood ·Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Guillermo Garcia‐Manero, Alfonso Quintás‐Cardama, Jenny Shan, Mary Beth Rios, Farhad Ravandi, Stefan Faderl, Tapan M. Kadia, Gautam Borthakur, Xuelin Huang, Richard E. Champlin, Moshe Talpaz, Jörge E. Cortes
2012235
5
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
Blood ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah A. Thomas, Jianqin Shan, Mary Beth Rios, Jörge E. Cortes
2002229
6
Imatinib mesylate (STI571) therapy for Philadelphia chromosome–positive chronic myelogenous leukemia in blast phase
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Maher Albitar, Mary Beth Rios, Jianqin Shan, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Debra Resta, Moshe Talpaz
2002227
7
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clinical Cancer Research ·Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis J. Giles, Stefan Faderl, Srđan Verstovšek, Guillermo Garcia‐Manero, Mary Beth Rios, Hagop M. Kantarjian
2005197
8
Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
Cancer ·Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Francis J. Giles, Stefan Faderl, Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Mary Beth Rios, Jianqin Shan, Michael Andreeff, Michael J. Keating, Moshe Talpaz
2003185
9
Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis
Cancer ·Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Jianqin Shan, Francis J. Giles, Mary Beth Rios, Stefan Faderl, William G. Wierda, Alessandra Ferrajoli, Srđan Verstovšek, Michael J. Keating, Emil J. Freireich, Moshe Talpaz
2003177
10
Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib
Journal of Clinical Oncology ·Patricia Ault, Hagop M. Kantarjian, Susan O’Brien, Stefan Faderl, Miloslav Beran, Mary Beth Rios, Charles Koller, Francis J. Giles, Michael J. Keating, Moshe Talpaz, Jörge E. Cortes
2006162
11
Chronic myelogenous leukemia in nonlymphoid blastic phase
Cancer ·Stefano Sacchi, Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Mary Beth Rios, Francis J. Giles, Miloslav Beran, Charles Koller, Michael J. Keating, Moshe Talpaz
1999155
12
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α
Blood ·Jörge E. Cortes, Francis J. Giles, Susan O’Brien, Deborah A. Thomas, Guillermo Garcia‐Manero, Mary Beth Rios, Stefan Faderl, Srđan Verstovšek, Alessandra Ferrajoli, Emil J. Freireich, Moshe Talpaz, Hagop M. Kantarjian
2003153
13
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
Blood ·Jörge E. Cortes, Moshe Talpaz, Francis J. Giles, Susan O’Brien, Mary Beth Rios, Jianqin Shan, Guillermo Garcia‐Manero, Stefan Faderl, Deborah A. Thomas, William Wierda, Allessandra Ferrajoli, Sima Jeha, Hagop M. Kantarjian
2003153
14
Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
Blood ·Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Daniel M. Jones, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jörge E. Cortes
2006152
15
Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers
Journal of Clinical Oncology ·Hagop M. Kantarjian, Varsha Gandhi, Peter Kozuch, Stefan Faderl, Francis J. Giles, Jörge E. Cortes, Susan O’Brien, Nuhad K. Ibrahim, Fadlo R. Khuri, Min Du, Mary Beth Rios, Sima Jeha, Peter McLaughlin, William Plunkett, Michael J. Keating
2003150
16
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Journal of Hematology & Oncology ·Kamal Chamoun, Hagop M. Kantarjian, Rami Atallah, Graciela Nogueras González, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia‐Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia, Naveen Pemmaraju, Elias Jabbour, Jörge E. Cortes
2019139
17
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-α
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Rajyalakshmi Luthra, Francis J. Giles, Srđan Verstovšek, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia‐Manero, Mary Beth Rios, Jianqin Shan, Dan Jones, Moshe Talpaz
2004130
18
Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia
Leukemia & lymphoma ·Elihu H. Estey, William Plunkett, Varsha Gandhi, Mary Beth Rios, Hagop Kantarjian, Michael J. Keating
1993129
19
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome–positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah Thomas, Sima Jeha, Mary Beth Rios, Laurie Letvak, Kathy Bochinski, Ralph B. Arlinghaus, Moshe Talpaz
2002125
20
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
Blood ·Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes, Sergio Giralt, Mary Beth Rios, Jianqin Shan, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Marcos de Lima, Guillermo Garcia‐Manero, Richard E. Champlin, Ralph B. Arlinghaus, Moshe Talpaz
2002125

About Mary Beth Rios

Mary Beth Rios is a scholar working on Hematology, Genetics, Rheumatology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health, having authored 129 papers that have together received 7.4k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (108 papers), Chronic Lymphocytic Leukemia Research (96 papers), Eosinophilic Disorders and Syndromes (72 papers), Acute Myeloid Leukemia Research (21 papers), Acute Lymphoblastic Leukemia research (18 papers), Lymphoma Diagnosis and Treatment (17 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). The work is most often cited by research in Hematology (6.3k citations), Genetics (5.0k citations), Rheumatology (3.5k citations), Public Health, Environmental and Occupational Health (1.2k citations) and Pathology and Forensic Medicine (652 citations). Mary Beth Rios has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Stefan Faderl, Guillermo Garcia‐Manero, Jianqin Shan, Srđan Verstovšek and Deborah A. Thomas. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan O’BrienBreakdown of academic impact, for papers by Jianqin ShanBreakdown of academic impact, for papers by Stephen G. O’BrienBreakdown of academic impact, for papers by Philipp le CoutreBreakdown of academic impact, for papers by Laurence LegrosBreakdown of academic impact, for papers by Haifa Kathrin Al‐AliBreakdown of academic impact, for papers by Zbigniew RudzkiBreakdown of academic impact, for papers by Miloslav BeranBreakdown of academic impact, for papers by H. KantarjianBreakdown of academic impact, for papers by Miloslav Beran